Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCDQX0)

• Drug Name: ND-0801 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMCDQX0

Molecule-Related Drug Atlas

Drug(s) Targeting Nicotinic acetylcholine receptor (nAChR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[3]
Cotinine	DMCEZ1B	Insecticide	N.A.	Approved	[4]
Pancuronium	DMB0VY8	Anaesthesia	9A78.6	Approved	[5]
Atracurium	DM42HXN	Anaesthesia	9A78.6	Approved	[5]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[6]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[7]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[8]
BMS-954561	DM7XV4R	Diabetic neuropathy	8C0Z	Phase 2	[9]
ASM-024	DM35S2I	Asthma	CA23	Phase 2	[10]
NIC-002	DMKLJMI	Nicotine dependence	6C4A.2	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acetylcholine receptor (nAChR)	TTJSZTB	NOUNIPROTAC	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01174355) A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD). U.S. National Institutes of Health.
• [2] Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table, 2013, Volume 27, Issue 4, 245-248.
• [3] Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
• [4] Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
• [5] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
• [6] Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [9] EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
• [10] Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
• [11] Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.